NeuroQure Launches Diagnostic Test To Assess Early Autism Risk

NeuroQure, a neurological diagnostics company, launched ASD Insight, a diagnostic test designed to assess autism risk beginning at birth. The test uses an optical patch clamp technique to analyze mitochondrial and neurotransmitter function associated with autism.

The test requires a skin biopsy, which is processed at NeuroQure’s Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. Results are returned to health care professionals within several weeks.

According to the company, earlier identification of autism risk may support earlier intervention. Research has shown that children who begin intervention at younger ages may experience improvements in cognitive and social development.

NeuroQure positions ASD . . .